Screening

Alpha technology

3 January 2018 | By PerkinElmer

Alpha (Amplified Luminescence Proximity Homogeneous Assay) bead-based technology for no-wash assays.

Application note: Development and utilisation of bromodomain and extra terminal domain (BET) assays using AlphaLISA technology

3 January 2018 | By Daniel Cardillo (PerkinElmer), Dawn Nida (PerkinElmer), Hong Cao (PerkinElmer), Jen Carlstrom (PerkinElmer)

In this application note, PerkinElmer demonstrates the ease and utility of using AlphaLISA®, a homogeneous assay format, to screen for small molecular inhibitors of BET bromodomains.

Video: PerkinElmer signals lead discovery

3 January 2018 | By PerkinElmer

Quickly gain new insights into chemical and biomolecular research data. Featuring guided search and analysis workflows and dynamic data visualisations.

Scientific poster: Developing protein: Protein Interaction (PPI) assays with AlphaLISA and LANCE TR-FRET

2 January 2018 | By Catherine Lautenschlager (PerkinElmer), Daniel Cardillo (PerkinElmer), Matthew Reuter (PerkinElmer)

In this scientific poster, PerkinElmer demonstrates the ease and utility of using AlphaLISA® and LANCE® TR-FRET homogenous assay forms for studying PPIs.

Using open science to develop Pediatric Cancer Drugs

2 January 2018 | By Charles River Laboratories

The webinar speakers highlight the collaboration between patient groups, charities, and academia led to the development of inhibitors targeting gliomas.

BMG Labtech GmbH

Assay may boost targeted treatment of non-hodgkin lymphoma

17 December 2017 | By Dr Zara Kassam (Drug Target Review)

Better subtyping of diffuse large B-cell lymphomas can enhance diagnosis and guide treatment...

Expert view: Conquering late stage failures with advanced hit-to-lead techniques

14 December 2017 | By Steven G Jarvis (Head of Pharma & Biotech Segment Strategy - MilliporeSigma)

Failing early in drug discovery is the primary driving force for new techniques in the hit-to-lead phase.

Using 3D cell cultures to fight anti-cancer therapy resistance

13 December 2017 | By Dr Zara Kassam (Drug Target Review)

An international team of researchers have developed 3D cell cultures in which genes can be specifically modified to improve the use of targeted anti-cancer drugs...

Patient-derived neural progenitor cells as a drug discovery model for mitochondrial diseases

13 December 2017 | By Alessandro Prigione, Carmen Lorenz, Gizem Inak

Mitochondrial DNA (mtDNA) mutations cause severe disorders that are untreatable and mostly affect the nervous system. The difficulty in funding therapies may also be explained by the lack of viable modelling systems...

Expert view: Optimising the hit-to-lead workflow

13 December 2017 | By Dr. Paul Wylie (Head of Applications at TTP Labtech)

Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.

Application note: Performing NanoBRET with the Varioskan LUX multimode reader

13 December 2017 | By Thermo Fisher Scientfic

In this paper, Thermo Fisher Scientific aim to assess the performance of Thermo Scientific Varioskan LUX when running NanoBRET.

Q&A: Implementing ADCC assays in QC: when donor variability isn’t an option

12 December 2017 | By Drug Target Review

DiscoverX recently introduced the single donor-derived KILR CD16 Effector Cells to ensure assay reproducibility for screening, characterisation, and QC lot release of antibody drugs.

A pragmatic approach to hit validation following biochemical high-throughput screening

12 December 2017 | By Dr Agnes Martin, Dr Laurent Rigoreau, Dr Sheila McLoughlin

Progressing actives from a high-throughput screen (HTS) of a target protein into suitable starting points for lead identification is fraught with pitfalls. The volume and quality of the HTS output is a function of the quality of the screening library, as well as specific properties of both the target and…

Expert view: Addressing the big challenges in drug screening

12 December 2017 | By Joesph Zock (Product Managemenr at IntelliCyt)

One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.